Professional
Added to YB: 2026-08-04
Pitch date: 2026-08-01
STVN [neutral]
Stevanato Group S.p.A.
+4.31%
current return
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Market Cap
$4.7B
Pitch Price
$19.74
Price Target
N/A
Dividend
0.31%
EV/EBITDA
17.13
P/E
33.84
EV/Sales
4.20
Sector
Life Sciences Tools and Services
Category
growth
(NYSE:STVN) Stevanato: Injectables Interrupted
STVN (pass): Neutral. Drug containment leader riding peptide/GLP-1 secular growth (22% of rev), #1 in RTU vials/cartridges, serves 23 of top 25 pharma. But Engineering segment drag (Q1'26 rev -31%, ~15% GM), oral GLP risk, low utilization (~30%) on €500M capacity. 20.6x EV/EBITDA, 34x P/E, 8% ROIC, 3% FCF yield—little margin for error.
Read full article (7 min)